GeneDx Holdings
About: GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
Employees: 1,000
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
147% more call options, than puts
Call options by funds: $62.7M | Put options by funds: $25.3M
81% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 32
44% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 59
39% more capital invested
Capital invested by funds: $1.81B [Q4 2024] → $2.51B (+$701M) [Q1 2025]
20% more funds holding in top 10
Funds holding in top 10: 10 [Q4 2024] → 12 (+2) [Q1 2025]
15.32% more ownership
Funds ownership: 85.66% [Q4 2024] → 100.98% (+15.32%) [Q1 2025]
12% more funds holding
Funds holding: 199 [Q4 2024] → 223 (+24) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$78
6%
downside
Avg. target
$99
19%
upside
High target
$115
39%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
Piper Sandler David Westenberg | 33%upside $110 | Overweight Initiated | 9 Jul 2025 |
Guggenheim Subbu Nambi | 39%upside $115 | Buy Maintained | 30 Jun 2025 |
Jefferies Tycho Peterson | 3%downside $80 | Buy Upgraded | 9 May 2025 |
TD Securities Dan Brennan | 33%upside $110 | Buy Maintained | 1 May 2025 |
Wells Fargo Brandon Couillard | 6%downside $78 | Equal-Weight Maintained | 1 May 2025 |
Financial journalist opinion
Based on 24 articles about WGS published over the past 30 days
Neutral
GlobeNewsWire
11 hours ago
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.
Neutral
PRNewsWire
1 day ago
Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS
NEW YORK , July 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public. So What: If you purchased GeneDx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Neutral
Business Wire
1 day ago
GeneDx to Report Second Quarter 2025 Financial Results on Tuesday, July 29, 2025
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) announced it will release financial results for the second quarter of 2025 before the market opens on Tuesday, July 29, 2025.
Neutral
GlobeNewsWire
4 days ago
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.
Neutral
GlobeNewsWire
1 week ago
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.
Positive
MarketBeat
1 week ago
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
The biopharmaceuticals space is notorious for sudden, sharp rallies, and for precipitous sell-offs as well. The industry is crowded with names, many of which are tiny firms working toward developing a small number of drug candidates and lacking a means of achieving profitability until one or more of those products make it to market.
Neutral
GlobeNewsWire
1 week ago
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, June 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.
Positive
The Motley Fool
2 weeks ago
Why GeneDX Stock Surged Higher This Week
Shares in genetic testing company GeneDx Holdings (WGS 0.74%) continued their wild ride in 2025 and are up almost 34% on the week to Friday morning. This week's move follows the American Academy of Pediatrics' (AAP) updated guidance, which recommends exome and genetic testing as a first-line test for children with global developmental delays (GDDs) and intellectual disabilities (IDs).
Neutral
GlobeNewsWire
2 weeks ago
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GeneDx Holdings Corp. (NASDAQ: WGS) resulting from allegations that GeneDx may have issued materially misleading business information to the investing public.
Positive
24/7 Wall Street
2 weeks ago
Insiders Invested Millions in these Five Rebounding Stocks
Marriott Vacations Worldwide director Christian Asmar bought 412,449 shares for just over $27.88 million.
Charts implemented using Lightweight Charts™